Last reviewed · How we verify
LUPKYNIS
LUPKYNIS (voclosporin) is a calcineurin inhibitor that suppresses T-cell activation and cytokine production to reduce lupus nephritis inflammation.
LUPKYNIS (voclosporin) is a calcineurin inhibitor that suppresses T-cell activation and cytokine production to reduce lupus nephritis inflammation. Used for Lupus nephritis (Class III or IV).
At a glance
| Generic name | LUPKYNIS |
|---|---|
| Also known as | voclosporin |
| Sponsor | Aurinia Pharmaceuticals Inc. |
| Drug class | Calcineurin inhibitor |
| Target | Calcineurin (via cyclophilin binding) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Nephrology |
| Phase | FDA-approved |
Mechanism of action
Voclosporin binds to cyclophilin and inhibits calcineurin, a phosphatase required for T-cell receptor signaling and IL-2 transcription. This suppresses the proliferation and activation of T lymphocytes, reducing the autoimmune response in lupus nephritis. By decreasing pathogenic T-cell activity, it reduces proteinuria and preserves kidney function in patients with lupus-induced kidney disease.
Approved indications
- Lupus nephritis (Class III or IV)
Common side effects
- Hypertension
- Hyperkalemia
- Increased serum creatinine
- Headache
- Diarrhea
- Tremor
- Gum hyperplasia
Key clinical trials
- LUPKYNIS Drug-use Results Survey
- Examining Distinct Immunophenotypes to Validate and Enhance Rational Treatment in Systemic Lupus (PHASE2)
- A Prospective Observational Registry of Patients Treated With LUPKYNIS® (Voclosporin) in the US
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LUPKYNIS CI brief — competitive landscape report
- LUPKYNIS updates RSS · CI watch RSS
- Aurinia Pharmaceuticals Inc. portfolio CI